Merck

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

At Qure.ai their mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients.

CancerIQ’s technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at canceriq.com.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Innovation in healthcare is hindered by the time and cost of bringing new products to market. Verana Health is partnering with medical associations to build a regulatory-grade data platform for health care innovation that utilizes specialty clinical data sets. Verana Health’s platform enables physicians and industry to work together towards their shared goal of accelerating the availability of better treatments and cures for patients. Learn more at veranahealth.com.

PreciseDx is a company specializing in cancer risk stratification by providing patient-specific risk assessments through the analysis of morphological features. Utilizing artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that offer detailed insights into each patient's risk profile and potential outcomes, thereby enhancing treatment decision-making. The company combines its clinical, regulatory, and translational research expertise to advance technologies in areas such as clinical modeling, patient phenotyping, and image analysis, ultimately aiming to improve patient outcomes and quality of life in the realm of cancer and other diseases.

Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.

Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company is known for luspatercept-aamt, marketed as REBLOZYL, which treats anemia in adult patients with beta-thalassemia. Additionally, it is developing luspatercept-aamt for myelodysplastic syndromes and myelofibrosis, while Sotatercept targets pulmonary arterial hypertension. Acceleron is also advancing ACE-083, a neuromuscular candidate in Phase II trials aimed at Charcot-Marie-Tooth disease. The company's research focuses on biotherapeutics that influence the growth of bone, muscle, fat, and blood vessels to address conditions such as cancer-related bone and muscle loss, as well as various metabolic disorders. Founded in 2003 and based in Cambridge, Massachusetts, Acceleron has established collaborations with Celgene Corporation and Fulcrum Therapeutics to enhance its therapeutic offerings in the pulmonary disease space.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine. Our Company was founded in 2006 at the Moffitt Cancer Center to operationalize the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. In this effort, we partner with the nation’s leading cancer centers via the Oncology Research Information Exchange Network (ORIEN).

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication. Oncolmmune was founded in 2000 and is based in Rockville, Maryland.

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Volansi, Inc. is a logistics and transportation company specializing in the manufacture of heavy-payload drones for commercial, defense, and humanitarian purposes. Founded in 2015 and headquartered in Concord, California, Volansi develops autonomous aerial delivery solutions that enable time-critical shipments over long distances. The company’s unmanned aerial vehicles are designed for various industries, including construction, oil and gas, mining, and healthcare, facilitating the rapid delivery of essential items such as spare parts and medical supplies. By offering fixed-route deliveries, Volansi addresses specific customer challenges related to time and cost, allowing businesses to enhance their operational efficiency.

Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

AeroSafe Global specializes in the development and production of aerogels and related materials designed for temperature-sensitive shipping needs. Operating primarily in the United States, the company addresses thermal insulation requirements for transporting biomedical, pharmaceutical, and other temperature-sensitive products. AeroSafe Global offers cold-chain services tailored for the biopharma industry, ensuring zero temperature excursions for clients and their products. Through proprietary packaging, logistics, and operational services, the company creates customized solutions that guarantee the safe delivery of sensitive biopharmaceuticals. Founded in 1995 and headquartered in Rochester, New York, AeroSafe Global also maintains additional offices in Kentucky, Nevada, Germany, and Canada.

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Tasso Inc. is a healthcare company based in Seattle, Washington, that specializes in developing clinical-grade, at-home blood collection devices. Founded in 2012, Tasso's innovative products enable individuals to collect their own blood samples with ease and privacy, using a device that allows for self-sampling at home. Once the sample is collected, users can mail it directly to a qualified laboratory for analysis, eliminating the need for clinic visits. Tasso's approach aims to enhance the blood-based diagnostics process by prioritizing convenience and user experience, thereby making healthcare more accessible.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company focused on creating immunotherapies for various human diseases. Established in 2014 and headquartered in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts, the company utilizes advanced antibody science to develop large-scale production platforms for immunoglobulins. Its product pipeline includes SAB-142, which targets Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 aimed at Middle East Respiratory Syndrome Coronavirus (MERS-CoV). SAB Biotherapeutics is committed to addressing public health challenges, rare conditions, long-term diseases, and potential global pandemic threats through innovative therapeutic solutions.

Preventice Solutions, Inc. is a provider of healthcare solutions specializing in mobile health technologies and services. Founded in 2007 and based in Eagan, Minnesota, the company offers a range of platforms, including the PatientCare Portal for real-time patient data management, the PatientView Portal for healthcare organizations, and the PatientFlow Portal for monitoring centers. Preventice is known for its advanced wearable monitoring devices, such as the BodyGuardian Heart, which enhances patient mobility and compliance, and the BodyGuardian Verité, a dual-modality cardiac sensor. These technologies aim to facilitate the monitoring and management of patients with cardiac issues, improving health outcomes while potentially reducing the cost of care. The company was formed through the merger of Preventice Services and Preventice Technologies in 2014, and it operates additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Ayogo Health Inc. develops games and applications for management of chronic health conditions and patient adherence. Its products include GoodLife, a customizable platform that uses tailor-made gamification components, incentives, and social features; and Alternate Reality Games, a suite of learning applications which combines online and real-world elements. The company was founded in 2008 and is based in Vancouver, Canada.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for cancer and rare diseases. Based in Burlington, Massachusetts, the company utilizes its ArQule Kinase Inhibitor Platform to create innovative small molecule drugs. ArQule's pipeline includes several promising candidates, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase currently in Phase I trials for B-cell malignancies, and miransertib (ARQ 092), which targets the AKT pathway in advanced endometrial cancer patients. Additionally, ARQ 75 is under Phase I development for solid tumors with specific genetic mutations, while Derazantinib (ARQ 087) is in a registrational trial for intrahepatic cholangiocarcinoma. The company has established licensing agreements with Basilea Pharmaceutica and Roivant Sciences for its products. Founded in 1993, ArQule has positioned itself as a key player in the oncology space, aiming to improve patient outcomes through its specialized therapeutics. As of early 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

She’s Well brings a Netflix-like subscription model to fertility, to help women, men, and couples to have children when they’re ready. The company works with its network of top-tier fertility centers to provide financing plans for fertility testing, IVF, egg freezing and sperm freezing. With an on-demand concierge care approach, She’s Well provides support and guidance, to make the fertility journey less confusing and isolating. 1 in 6 couples has trouble conceiving and we’re waiting longer to try. Women increasingly delay childbirth - one in three women in the U.S. has her first child after 30 and one in ten after 35. Male sperm count has decreased over 50 percent in the last decade. Despite all the solutions available on the market, infertility services remain available to only 1%. Health plans usually don't cover infertility treatments. The typical costs range from 12,000 to 20,000 dollars for IVF, plus another few thousand for the genetic testing involved to ensure the fetus is chromosomally normal. To help, She’s well started out offering subscription plans and concierge guidance to make fertility care more affordable and accessible to the 99%. We need to usher a world where decisions about family and career aren't ruled by biological clocks and where the best options, science, and care are available to everyone who wants to start a family.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

CIOX Health, LLC is a healthcare services company based in Alpharetta, Georgia, specializing in the management and exchange of health information. The firm operates a cloud-based platform that digitizes and organizes both structured and unstructured medical records, facilitating access to clinical data for various stakeholders, including healthcare providers, health plans, and government agencies. CIOX offers a range of services including information release, medical record retrieval, coding and education, and risk adjustment solutions. Their expertise is designed to improve patient outcomes while ensuring compliance with regulations regarding the release of medical information. CIOX Health serves a diverse clientele, including hospitals, physician practices, law firms, and life insurance companies, making it a key player in the healthcare information management sector. The company was established in 1976 and operates additional locations in Phoenix, Arizona, and Green Bay, Wisconsin.

Tilos Therapeutics, Inc. is a biotechnology company focused on developing antibody therapeutics aimed at treating cancer. Established in 2016 and based in Lexington, Massachusetts, the firm specializes in anti-LAP antibodies that target key immunological pathways, particularly regulatory T cells and the regulation of effector cells. Its primary research involves antibodies specific for the Latency Associated Peptide of TGF beta, which plays a critical role in immune regulation. As of mid-2019, Tilos Therapeutics operates as a subsidiary of Merck & Co., Inc.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing therapeutics for bone-related diseases. The company employs a unique prodrug platform to selectively deliver bi-specific small-molecule therapeutics, targeting both specific tissues and molecular sites. This targeted delivery minimizes side effects associated with systemic drug exposure. One of its notable products, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to potentially reverse bone loss associated with conditions such as Duchenne muscular dystrophy and osteoporosis. Mesentech's proprietary bone targeting system addresses the challenges of treating bone due to its hard surface and low porosity, which complicate drug delivery. Pre-clinical studies have demonstrated the effectiveness of this technology, positioning Mesentech as a key player in the development of innovative treatments for difficult-to-treat bone diseases. The company was incorporated in 2013.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, focused on developing innovative medicines for cancer and other serious conditions. The company's lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, Peloton is exploring PT2977 in various other indications, including von Hippel-Lindau disease-associated renal cell carcinoma and glioblastoma multiforme, as well as in combination therapies for metastatic renal cell carcinoma. Furthermore, Peloton is developing PT2567, another oral HIF-2a inhibitor in preclinical stages aimed at non-oncology applications, notably pulmonary arterial hypertension. Founded in 2010 and initially known as Damascus Pharmaceutics, Peloton Therapeutics has formed strong partnerships with academic institutions and secured funding from organizations like the Cancer Prevention Research Institute of Texas, positioning itself as a key player in the biotech sector.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.

Clinithink Ltd develops cloud based data analytics software for healthcare sector. Its product includes CLiX ENRICH, a platform which collects clinical trial data using structured tools and methodologies, records data in their preferred narrative style, and enables content indexing. It also offers CLiX RARE for diagnosing genetic disorders in newborns. The company serves healthcare providers, pharmaceutical companies, and content vendors. Clinithink Ltd was founded in 2009 and is based in Bridgend, United Kingdom.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Kytopen Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on advancing cell therapy through its innovative Flowfect technology. Established in 2017, Kytopen specializes in non-viral delivery systems for molecules into challenging immune cells that are typically hard to transfect. The company utilizes a combination of microfluidics and automation to streamline the delivery process, making it faster, more efficient, and cost-effective. By employing a unique platform that integrates continuous fluid flow with electric fields, Kytopen enables researchers to produce high-quality engineered cells in a matter of minutes while preserving their health and functionality. This approach supports the discovery of novel biological insights and the development of affordable cell and gene therapies.

Antelliq designs, manufactures, and distributes animal intelligence solutions for the management of livestock, pets, and fish. It provides digital animal identification, traceability, and monitoring solutions. The company’s solutions help veterinarians, farmers, and pet owners gather critical data to improve management, health, and well-being of livestock and pets. It provides its products under Allflex, Sure Petcare, and Biomark brand names. The company was incorporated in 2013 and is based in Vitré, France. As of April 1, 2019, Antelliq operates as a subsidiary of Merck Animal Health.

ClearDATA is the trusted managed cloud provider, designed for today’s healthcare security needs. More than 350,000 healthcare professionals trust the ClearDATA HIPAA-compliant cloud to safeguard their patient data and power their critical applications. ClearDATA protects sensitive healthcare data using compliance and security safeguards, purpose-built DevOps automation, and healthcare expertise — all backed by managed cloud services. This ensures healthcare organizations, and the technology providers that support them, are adhering to the highest standards in privacy, security and compliance in the cloud.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Quit Genius is a digital behavior change platform for addictions with industry-leading quit rates. Founded in 2017 by medical doctors, the program for tobacco, e-cigarettes, alcohol and substance use disorder uses a disruptive model to deliver best practice care via digital cognitive behavioral therapy (CBT), expert coaching, a connected breath sensor and easy access to proven medication.

Livongo is the consumer digital health company that empowers people with chronic conditions to live a better life. It has developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights, and support to make diabetes management easier. Its approach is leading to better financial and clinical outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. It was founded in 2008 and is headquartered in Mountain View, California.

Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia. Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Prognos is a healthcare AI company dedicated to improving disease management through early intervention in collaboration with payers, life sciences, and diagnostics companies. It operates the Prognos Registry, which is the largest repository of clinical diagnostics information, encompassing over 5 billion medical records across more than 30 disease areas and covering 100 million patients. The company has developed 500 proprietary clinical algorithms that facilitate the early identification of patients, thereby enhancing treatment decision-making and risk management. Its platform, prognosFACTOR, efficiently analyzes vast amounts of lab and health records from over 325 million de-identified patients, providing rapid answers to clinically-focused healthcare inquiries. Prognos offers HIPAA-compliant healthcare data through its Prognos Marketplace, catering to various applications such as cohort design and health outcomes analysis, with a client base that includes a significant number of leading pharmaceutical manufacturers and payers.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.

Serimmune Inc., a biotechnology company, develops diagnostics and therapeutics for autoimmune diseases. It offers serum epitope repertoire analysis (SERA) technology platform that applies bacterial display peptide libraries, sequencing, machine learning, and custom bioinformatics to reveal the diverse antigens stimulating immunity. It maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, micro biome organisms, autoimmune diseases, and cancers. The company was founded in 2014 and is based in Goleta, California.

ClearDATA is the trusted managed cloud provider, designed for today’s healthcare security needs. More than 350,000 healthcare professionals trust the ClearDATA HIPAA-compliant cloud to safeguard their patient data and power their critical applications. ClearDATA protects sensitive healthcare data using compliance and security safeguards, purpose-built DevOps automation, and healthcare expertise — all backed by managed cloud services. This ensures healthcare organizations, and the technology providers that support them, are adhering to the highest standards in privacy, security and compliance in the cloud.

Livongo is the consumer digital health company that empowers people with chronic conditions to live a better life. It has developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights, and support to make diabetes management easier. Its approach is leading to better financial and clinical outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. It was founded in 2008 and is headquartered in Mountain View, California.

Arcadia is a population health management company, specializing in data aggregation, analytics, and workflow software for value-based care. Its customers achieve financial success in their risk-sharing contracts through Arcadia’s focus on creating the highest quality data asset, pushing expertly derived insights to the point of care, and supporting administrative staff with data when and where they need it with applications including care management and referral management. Arcadia has off-the-shelf integration technology for more than 40 different physical and behavioral health EHR vendors, powered by machine learning that combs through variations in over 60 million longitudinal patient records across clinical, claims, and operational data sources.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.

StayWell is a health engagement company that helps its clients engage and educate people to improve health and business results. We bring decades of experience working across the health care industry to design solutions that address our clients’ evolving needs. StayWell fuse expertise in health engagement and the science of behavior change with an integrated portfolio of solutions and robust content assets. Our customizable programs are proven to effectively engage people to make positive health care decisions—across even the most challenging populations. StayWell want you to know your programs are working—and see unmistakable benefits. A passion for data is at the heart of what we do and informs every stage of our work from program design to implementation to continual performance review. That’s why our clients across the health spectrum know us for results: diminished health costs, accelerated group participation, increased patient acquisition, better health outcomes and unprecedented program satisfaction.

Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, focused on developing molecular diagnostics and informatics to address infectious diseases. The company produces various products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance in urine and other samples, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. OpGen also offers the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to provide insights for managing multidrug-resistant organisms in healthcare settings. The company collaborates with the New York State Department of Health to enhance detection and management of antimicrobial-resistant infections in healthcare institutions. Additionally, OpGen is advancing DNA analysis and genomics through its Argus Whole Genome Mapping System and MapIt Services, catering to academic and research sectors worldwide. Founded in 2001, OpGen aims to improve patient outcomes and reduce the spread of infections caused by resistant microorganisms.

medCPU, Inc. delivers real-time clinical care advice through its Advisor Button technology for hospitals in the United States. Its Advisor Button captures the clinical picture from clinicians’ free-text notes, dictations, and structured documentation entered into EMR and analyzes it against a growing library of content for generating real-time precise prompts for care consideration; medCPU platform captures the clinical picture in real time, including narrative text and structured data to deliver the clinical and compliance guidance

Livongo is the consumer digital health company that empowers people with chronic conditions to live a better life. It has developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights, and support to make diabetes management easier. Its approach is leading to better financial and clinical outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. It was founded in 2008 and is headquartered in Mountain View, California.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

IOmet Pharma Ltd. discovers and develops medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. It develops IDO, TDO, and dual-acting IDO/TDO inhibitors, as well as GLUT1 inhibitors. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in London, United Kingdom. As of January 11, 2016, IOmet Pharma Ltd. operates as a subsidiary of Merck & Co., Inc.

WellDoc, Inc. specializes in developing technology solutions aimed at managing chronic diseases, particularly diabetes. The company offers DiabetesManager, a patient-centric platform designed to facilitate the coordination of diabetes care between patients and healthcare providers. This platform includes features such as personalized coaching, medication reminders, alerts for out-of-range metrics, and family connectivity, all supported by cloud-based analytics and clinical decision-making tools. Additionally, WellDoc provides BlueStar, a mobile prescription therapy solution that offers real-time guidance for diabetes self-management. The company supports a variety of stakeholders, including private and public payors, pharmaceutical firms, and healthcare systems, with services that encompass clinical requirements, software development, and behavioral health programs. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc aims to enhance patient outcomes and reduce healthcare costs by integrating clinical and behavioral applications with everyday technologies.

Exostar is a leader in secure cloud-based solutions that improve collaboration, information sharing, and supply chain management for over 100,000 companies worldwide, including some of the largest players in aerospace and defense, life sciences, pharmaceuticals, and financial services. Our secure, cloud-based, single-sign-on identity and access management platform and our multi-enterprise collaboration solutions allow users to connect once and access all their critical applications and information across the spectrum of partners and vendors they work with. Exostar helps our customers utilize and protect their intellectual property, streamline the partner lifecycle, implement new engagements, and expedite all phases of their supply chain.

CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

medCPU, Inc. delivers real-time clinical care advice through its Advisor Button technology for hospitals in the United States. Its Advisor Button captures the clinical picture from clinicians’ free-text notes, dictations, and structured documentation entered into EMR and analyzes it against a growing library of content for generating real-time precise prompts for care consideration; medCPU platform captures the clinical picture in real time, including narrative text and structured data to deliver the clinical and compliance guidance

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, focused on developing molecular diagnostics and informatics to address infectious diseases. The company produces various products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance in urine and other samples, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. OpGen also offers the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to provide insights for managing multidrug-resistant organisms in healthcare settings. The company collaborates with the New York State Department of Health to enhance detection and management of antimicrobial-resistant infections in healthcare institutions. Additionally, OpGen is advancing DNA analysis and genomics through its Argus Whole Genome Mapping System and MapIt Services, catering to academic and research sectors worldwide. Founded in 2001, OpGen aims to improve patient outcomes and reduce the spread of infections caused by resistant microorganisms.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's key product candidates include tebipenem pivoxil hydrobromide, an oral antibiotic aimed at treating MDR gram-negative infections in adults; SPR206, an intravenous agent targeting MDR gram-negative infections in hospital settings; and SPR720, an oral antibiotic for pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has entered various agreements, including a licensing partnership with Meiji Seika Pharma to develop tebipenem HBr and collaborations with Everest Medicines and the Bill & Melinda Gates Medical Research Institute for the development and commercialization of SPR206 and SPR720, respectively. Founded in 2013, Spero Therapeutics aims to address urgent medical needs through innovative therapeutic solutions for serious bacterial infections.

ClearDATA is the trusted managed cloud provider, designed for today’s healthcare security needs. More than 350,000 healthcare professionals trust the ClearDATA HIPAA-compliant cloud to safeguard their patient data and power their critical applications. ClearDATA protects sensitive healthcare data using compliance and security safeguards, purpose-built DevOps automation, and healthcare expertise — all backed by managed cloud services. This ensures healthcare organizations, and the technology providers that support them, are adhering to the highest standards in privacy, security and compliance in the cloud.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Ayogo Health Inc. develops games and applications for management of chronic health conditions and patient adherence. Its products include GoodLife, a customizable platform that uses tailor-made gamification components, incentives, and social features; and Alternate Reality Games, a suite of learning applications which combines online and real-world elements. The company was founded in 2008 and is based in Vancouver, Canada.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics to address cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company leverages insights from human clinical and genetic data to create innovative therapies, particularly targeting conditions like type 2 diabetes and non-alcoholic steatohepatitis (NASH). Key product candidates include Aldafermin, currently in Phase 2b trials for NASH, and NGM313, an antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates under development aim to tackle a variety of health issues, including metabolic syndrome and cancer-related conditions. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and product development efforts. Established in 2007 and based in South San Francisco, California, the company is committed to translating complex biological insights into meaningful medical advances.

Liaison Technologies provides data management and integration solutions to integrate, transform, harmonize, manage, and secure critical business data on-premise or in the cloud. It offers business-to-business and application-to-application integration, and data transformation services; on-premise and cloud-based data security solutions; cloud integration brokerages, and data aware cloud services; data harmonization solutions; cloud-based master data management; architecture-based B2B integration network; and compliance solutions. Liaison Technologies offers its solutions for the secure exchange of patient data between providers, payers, patients, and other healthcare organizations; for life science research endeavors; and to integrate and manage mission-critical data to improve efficiencies in forecasting, inventory management, material procurement, stock replenishment, order fulfillment, and other manufacturing processes. In addition, it provides data cleansing, semantic parsing, and up-to-the-minute product data; and electronic documents for handling and providing communications between manufacturers, distribution centers, shippers, transportation carriers, and other companies. Further, Liaison Technologies offers managed, cloud, professional, and cost optimization services, as well as planning, implementation, and other services. It serves healthcare, life sciences, manufacturing, retailers, consumer product goods providers and suppliers, logistics and distribution, and financial services companies in the United States and internationally. ForestExpress began operation in 2000 that became Liaison Technologies in April 2004. Its headquarters is in Alpharetta in Georgia with additional offices in Carbondale in Illinois, Santa Barbara and Silicon Valley in California; Seattle in Washington, Helsinki and Tampere in Finland, Nottingham in the United Kingdom, Amsterdam, the Netherlands; Stockholm, Sweden; and Singapore.

Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Aventura intelligently orchestrates assets, people, and systems to deliver the right information at the right time based on location and credentials. It locates and re-assigns the closest online printer and uniquely manages print routing to make it easier to detect and fix printing failures. Aventura was formed in 2007 and headquartered in Denver, Colorado.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Cubist Pharmaceuticals is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in acute care settings. The company is known for marketing CUBICIN (daptomycin for injection), a groundbreaking antibiotic in the lipopeptide class, as well as ENTEREG (alvimopan), which facilitates gastrointestinal recovery after certain surgeries. Cubist also promotes MERREM I.V. (meropenem for injection), an established antibiotic developed by AstraZeneca. Its product pipeline includes ecallantide, currently in Phase 2 clinical trials, and ongoing research focused on reducing blood loss during cardiac surgery. Additionally, the company is exploring treatments for Clostridium difficile-associated diarrhea and multi-drug resistant Gram-negative infections. In collaboration with Alnylam Pharmaceuticals, Cubist is also developing novel therapies for respiratory syncytial virus infections using RNA-interference technology. Founded in 1992 and headquartered in Lexington, Massachusetts, Cubist Pharmaceuticals continues to advance its mission of improving patient outcomes in acute care environments.

Imago BioSciences, based in San Carlos, California, is a biotechnology company focused on developing innovative therapies for hematologic diseases, including bone marrow failure, leukemia, myelodysplastic syndrome, and acute myelogenous leukemia. Founded in 2012, the company specializes in medicines that target genetic and epigenetic mechanisms to alter gene expression patterns, aiming to create transformative treatments for conditions that present significant challenges to patients and healthcare providers. By leveraging a skilled team and robust financial backing, Imago BioSciences is dedicated to addressing a select group of orphan diseases, striving to improve patient outcomes and enhance the quality of life for those affected.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

WiserTogether’s personalized healthcare treatment comparison software enables consumers to choose the right treatment – most effective in the outcome, most personally suitable, and most cost-effective and affordable. The result is improved health and improved costs for consumers, their employers, payers, and providers. The company serves over 3 million people through their employers and health plans. It was founded in 2008 and is based in Washington, District of Columbia.

Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.